Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
153.14 +0.53 (+0.35%) 02/27/25 [NASDAQ]
94.96 x 100 241.90 x 100
Realtime by (Cboe BZX)
94.96 x 100 241.90 x 100
Realtime - - (-) -
Quote Overview for Thu, Feb 27th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
152.17
Day High
155.04
Open 152.50
Previous Close 152.61 152.61
Volume 239,800 239,800
Avg Vol 532,430 532,430
Stochastic %K 87.43% 87.43%
Weighted Alpha +2.95 +2.95
5-Day Change -1.44 (-0.93%) -1.44 (-0.93%)
52-Week Range 111.09 - 157.37 111.09 - 157.37
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,261,747
  • Shares Outstanding, K 60,689
  • Annual Sales, $ 393,500 K
  • Annual Income, $ -409,120 K
  • EBIT $ -302 M
  • EBITDA $ -282 M
  • 60-Month Beta 0.64
  • Price/Sales 23.37
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 38.51% ( +0.37%)
  • Historical Volatility 56.70%
  • IV Percentile 17%
  • IV Rank 10.85%
  • IV High 118.25% on 04/17/24
  • IV Low 28.80% on 09/23/24
  • Put/Call Vol Ratio 0.96
  • Today's Volume 55
  • Volume Avg (30-Day) 143
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 6,239
  • Open Int (30-Day) 5,825

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.55
  • Number of Estimates 8
  • High Estimate -1.11
  • Low Estimate -1.84
  • Prior Year -2.48
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.03 +29.75%
on 02/12/25
Period Open: 126.05
157.37 -2.69%
on 02/18/25
+27.09 (+21.49%)
since 01/27/25
3-Month
118.03 +29.75%
on 02/12/25
Period Open: 136.32
157.37 -2.69%
on 02/18/25
+16.82 (+12.34%)
since 11/27/24
52-Week
111.09 +37.85%
on 09/12/24
Period Open: 155.34
157.37 -2.69%
on 02/18/25
-2.20 (-1.42%)
since 02/27/24

Most Recent Stories

More News
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

ASND : 153.14 (+0.35%)
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

TCAF : 33.20 (-1.54%)
ASND : 153.14 (+0.35%)
IBB : 135.48 (-1.14%)
HRTS : 30.44 (-0.29%)
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

ASND : 153.14 (+0.35%)
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

ASND : 153.14 (+0.35%)
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

ASND : 153.14 (+0.35%)
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

ASND : 153.14 (+0.35%)
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

ASND : 153.14 (+0.35%)
Ascendis Pharma A/S Announces U.S. Commercial Availability of YORVIPATH® for Hypoparathyroidism Treatment

Ascendis Pharma announces YORVIPATH's FDA approval and availability for treating adult hypoparathyroidism in the U.S.Quiver AI SummaryAscendis Pharma A/S has announced that its medication YORVIPATH® (palopegteriparatide),...

ASND : 153.14 (+0.35%)
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

ASND : 153.14 (+0.35%)
Ascendis Pharma Reports Positive Week 26 Results for TransCon hGH in Turner Syndrome Clinical Trial

The Phase 2 trial of TransCon hGH in Turner syndrome showed comparable safety and growth benefits to daily somatropin.Quiver AI SummaryAscendis Pharma announced positive results from the Week 26 analysis...

ASND : 153.14 (+0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 157.60
2nd Resistance Point 156.32
1st Resistance Point 154.73
Last Price 153.14
1st Support Level 151.86
2nd Support Level 150.58
3rd Support Level 148.99

See More

52-Week High 157.37
Last Price 153.14
Fibonacci 61.8% 139.69
Fibonacci 50% 134.23
Fibonacci 38.2% 128.77
52-Week Low 111.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements